JNJ Johnson & Johnson

$JNJ $MRNA $SLS MRNA Shorts have been squeezed from $25 to $243+ on there Phase 3 cancer vaccine success. $SLS will ascend in the same pattern in the coming hours and days ahead as we approach The next Chapter. ✌️🙏❤️‍🩹

$JNJ $SLS $MRK This is Merck's war to lose, and J&J is the wolf at the door. If Johnson & Johnson captures the $SLS platform, Merck ($MRK) faces absolute oncological extinction.

$JNJ $MRNA $SLS Moderna Rise from the Ashes due to it’s Cancer vaccine success which is partnered with $MRK 50/50 should put fear of God in every short. $SLS owns GPS outright 100% will Put fear of god in the coming days. Shorts will be liquidated here very soon. Shorts are running out of time. ⌛️ ✌️🙏❤️‍🩹

$JNJ $SLS The higher their share price the more currency they have. Whoever acquires SLS will almost immediately start 5-10 new trials for each asset if not more.

$JNJ $MRNA $SLS Shorts got 20 minutes to close there positions or get liquidated while trying. Time just ran out. 🔥 ✌️🙏❤️‍🩹

$JNJ NOV20 265C · still actionable Zone: $252.01 to $255.57 Invalidation: close under $245.17 Objectives: $265.35, then $281.07 The math: up 4.6% to the first objective and 10.7% to the second, against 3.4% risk on the invalidation, better than 3 to 1 to the second Dear friend, picture a big steady company that just took a hard knock and then stood back up. Johnson and Johnson beat its October 13 earnings estimate and the stock fell to $245.17 that day, then buyers stepped in and held the price above that low through a choppy week. That is a swing setup to me, a washed out name holding a real level with room to walk back toward $265.35 first. What that means is simple, we risk a close under the earnings day low to see if the bounce can grow legs. P.S. Watch $251.50, the low from the latest session, because holding above it keeps the bounce picture clean.

$JNJ $AVR J&J has spent roughly $30B building a heart business and still doesn't have a valve. Abiomed: ~$16.6B (2022) Shockwave: ~$13.1B (2024) Laminar: $400M upfront (2023) Atraverse: announced this year And Q3 wasn't pretty. MedTech grew 2.5%, below their own targets. Cardio slowed to 4.3% after running double digits. Abiomed actually shrank 2.3%. Schmid: "we can do better, and we absolutely will." That's heart recovery, circulation, rhythm and LAA covered. No TAVR. They're the only major cardio player sitting out one of the biggest device markets in cardiology. Everyone else is picking a balloon-expandable bet. BSX put $1.5B into MiRus. Medtronic took a stake in Anteris. Abbott is building its own, still at 11 patients in feasibility. Wolk on the call: "We always are on the lookout for strategic drivers that could complement our business." Not many independent BE platforms with real data left, let alone differentiated like duravr! This is masqueraded on purpose imo

$JNJ NOV20 265C · still actionable Zone: $253.77 to $257.35 Invalidation: close under $245.17 Objectives: $264.39, then $281.07 The math: up 3.5% to the first objective and 10.0% to the second, against 4.1% risk on the invalidation, about 2.4 to 1 to the second Think of this swing setup like a sturdy old house that took a loud knock on the door and did not move. Johnson and Johnson reported earnings on October 13 and beat what analysts expected, yet price dipped to $245.17 that day before buyers stepped back in and carried it to a $255.56 close on Friday, up 0.9 percent that day. What that means is simple. The low after the report is now our floor, and above us sits the $264.39 high from before the report and then the $281.07 yearly high. If price closes under $245.17 that floor has given way and you step aside. P.S. Watch $254 on Monday. It was the low on Friday, and a second hold there would show buyers are still defending the recovery.

$JNJ will go up at least through the election as a safe haven from election uncertainty. likely rotation from tech sector if democrats take the house due to perceived hostility to data center buildout. republicans retaining power is short term broad-sector bearish due to threats of new iran war, bullish for defense, possible minor bullish for safe haven stocks. democrats taking power is short term bullish if it prevents a new iran war + depending how much democrats gain potential long term bullish if it means increased healthcare spending.

$JNJ #ESMO Johnson & Johnson advances the next generation of solid tumor therapies with new data at ESMO 2026. First readout following acquisition of the RIPTAC™ platform shows promising anti-tumor activity with JNJ-6143, a novel oral investigational molecule, in difficult-to-treat prostate cancer. It offers a completely new way of thinking about cancer therapy.

$JNJ FDA approval Johnson & Johnson announces U.S. FDA Approval of RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) as First and Only Dual-Targeted Therapy for Advanced Head and Neck Cancer "Accelerated approval based on data demonstrating clinically meaningful efficacy, including a 42 percent overall response rate (95 percent confidence interval, 32–52 percent"

$JNJ This will be a lot higher next week with rotation out of technology stocks and into blue chip, defensive, safe quality with great dividend payout to boot🚀🚀🚀🚀

$JNJ 68,029 talc cases were pending in mdl 2738 as of june 1, per open class actions. lawsuit stage, no nationwide settlement, nothing to claim. seems like legacy bills outlast growth stories

So will $JNJ just forever keep going up?! Looking to see a break under $282 for put entry towards ~$275 then $262.45

$JNJ: no talc claim portal exists. With MDL 2738 still in mediation and no global deal, ovarian cancer cases move only as individual suits after attorney review. J&J denies the allegations. Open Class Actions.

$JNJ why did this suddenly double is there any fundamental change or is this just a sign of the times -

$JNJ: a leadership fight is still shaping the talc MDL. On May 26 the court denied Beasley Allen a stay of its disqualification in MDL 2738. Mediation continues, no global settlement, nothing to claim. Open Class Actions.

$JNJ Rybrevant cancer treatment is a second drug rolled out today signaling reduction in head and neck plus the prostate cancer breakthrough 🚀🚀🚀🚀🚀$300 this week

$JNJ $XLV $IHE JNJ - Weekly Chart The "bull flag" pattern is often ( though not always) a continuation formation. A commonly used measured-move technique among discretionary traders is to add the length of the flagpole to the breakout level of the flag. Applying that framework here suggests a "potential" longer-term upside objective in the $340 -$345 ish range, based on an approximately 100-point flagpole advance added to the $240 breakout area. Measured-move targets should always be viewed as guideline objectives rather than forecasts and should be approached with appropriate risk management. However, JNJ's successful retest and acceptance of former resistance levels near $263 and $270, combined with constructive weekly momentum, reinforces confidence that the broader uptrend remains intact and that buyers continue to defend higher price levels.

$JNJ has once again struggled and rejected the $280 resistance area A break of $278.75 is the put trigger targeting $275.25 then $271.35